SCHOTT, a specialty glass and international technology group, continues to expand its presence in North America to align operations and accelerate global profitability.
 
SCHOTT’s Pharmaceutical Systems business unit in Lebanon, PA contributed to the global COVID-19 response, increasing manufacturing capacity to meet the needs of vaccine makers. The Pennsylvania plant also supplies the growing demand of high-value products such as adaptiQ ready-to-use vials and EVERIC pure for highly potent drugs such as cancer medication. As part of a multimillion-dollar investment in the U.S. this past fiscal year, the facility underwent upgrades and expanded capacity for vial production.
 
Also, SCHOTT MINIFAB’s acquisition of Applied Microarrays Inc. (AMI) added cutting-edge biotech capabilities for diagnostics applications along with a production hub in Arizona.

“Our flexibility and commitment to a strategy of innovation will only strengthen our U.S. operations moving forward. With seven production sites, one R&D center, a sales office, and roughly 1,000 employees in the U.S., SCHOTT is well established,” said Dr. Heinz Kaiser, board member at SCHOTT and responsible for the group’s business in North America. “Over the past several years, we have invested $60 million in the U.S., and additional investments will accelerate our strategy of profitable growth and allow us to concentrate our activities on markets where we expect strong, sustainable development.”